Haemoprotection against cytostatic drugs by stem cell inhibition
| Autor: | Walter R. Paukovits, Marie-Hélène Moser |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Pharmacology
Chemotherapy Necrosis medicine.medical_treatment Antineoplastic Agents Neutropenia Biology Toxicology medicine.disease Hematopoietic Stem Cells Hematologic Diseases Haematopoiesis medicine.anatomical_structure Immunology medicine Cancer research Animals Humans Bone marrow Stem cell medicine.symptom Macrophage inflammatory protein Transforming growth factor |
| Zdroj: | Trends in pharmacological sciences. 12(8) |
| ISSN: | 0165-6147 |
| Popis: | Cytostatic drug-induced haematopoietic damage is a major problem in tumour chemotherapy, due to the intensive proliferation of many bone marrow constituents and to the drug-induced recruitment of immature pluripotent haematopoietic cells (spleen colony-forming units, CFU-S). Marie-Helene Moser and Walter Paukovits discuss how it should be possible to minimize such proliferation-associated damage by inhibiting CFU-S during the most dangerous treatment phases, with factors such as transforming growth factor β, tumour necrosis factor α, macrophage inflammatory protein 1α, and the CFU-S-inhibitory peptides N -acetyl-Ser-Asp-Lys-Pro and pyroGlu-Glu-Asp-Cys-Lys (pEEDCK). Clinically relevant data are available for pEEDCK, showing that application of this peptide leads to a delayed, shorter, and less severe neutropenia, combination of pEEDCK with a stimulator avoids neutropenia, and stem cell preservation with pEEDCK improves long-term reconstitution of the haematopoietic system. Stem cell inhibition by synthetic peptides like pEEDCK may provide a useful strategy for bone marrow protection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|